I agree. There are also factors related only to trial conduct that affects the analysis. For example, about 10% of the 9902a treatment arm did not get fully treated. That got to have some confounding effect on the final results. Hopefully IMPACT will do better with that. In addition, with a much larger enrollment number, the imbalances will be less pronounced.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.